Skip to main content
Qualigen Therapeutics, Inc. logo

Qualigen Therapeutics, Inc. — Investor Relations & Filings

Ticker · QLGN ISIN · US74754R1032 US Professional, scientific and technical activities
Open in API
Filings indexed 618 across all filing types
Latest filing 2015-05-08 Capital/Financing Update
Country US United States of America
Listing US QLGN

About Qualigen Therapeutics, Inc.

https://qlgntx.com/

Qualigen Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for cancer. The company's efforts are directed toward creating therapeutics for both adult and pediatric patients, with a particular emphasis on rare cancers and areas of high unmet medical need. Its development approach combines internal capabilities with collaborations from major cancer research institutions. The company's investigational oncology pipeline includes programs such as QN-302, a Pan-RAS inhibitor platform, and QN-247.

Recent filings

Filing Released Lang Actions
AMENDMENT NO. 2 TO FORM S-1
Capital/Financing Update Classification · 100% confidence The document is titled 'AMENDMENT NO. 2 TO FORM S-1' and is a registration statement filed with the U.S. Securities and Exchange Commission (SEC) under the Securities Act of 1933. It includes detailed information about the company's securities offering, including the number of shares, offering price, underwriting details, risk factors, business description, management, and financial statements. The Form S-1 is a registration statement used for initial public offerings (IPOs) and other securities offerings. This document is not a financial report like an annual or quarterly report, nor is it an earnings release or a management discussion. It is a regulatory filing related to the company's capital raising activities. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, consistent with a capital raising filing rather than a brief announcement or a report publication announcement.
2015-05-08 English
Regulatory Filings 2015
Regulatory Filings
2015-05-07 English
Regulatory Filings 2015
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from a company to the SEC staff regarding comments on a Registration Statement on Form S-1. It discusses amendments to the Registration Statement, clinical trial disclosures, stock-based compensation, valuation methods, and IPO pricing. The document references the Form S-1 registration process, which is related to an initial public offering (IPO) filing. It is not a financial report like an Annual Report or Interim Report, nor is it a simple announcement or certification. The content is regulatory in nature, addressing SEC comments and amendments to a registration statement, which fits the category of Regulatory Filings (RNS). The document is lengthy and substantive but does not contain financial statements or earnings data itself, nor is it a proxy, governance, or management report. Therefore, the best classification is Regulatory Filings (RNS).
2015-04-24 English
AMENDMENT NO. 1 TO FORM S-1
Regulatory Filings Classification · 100% confidence The document is titled "Amendment No. 1 to Form S-1" and is a registration statement filed with the U.S. Securities and Exchange Commission (SEC) under the Securities Act of 1933. It includes detailed information about the company's business, risk factors, management, capitalization, use of proceeds, and other disclosures typical of an S-1 registration statement used for an initial public offering (IPO). The document is not a financial report like an annual or quarterly report, nor is it an earnings release or a management discussion. It is a regulatory filing specifically related to securities registration and offering. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it contains substantive content, not just an announcement or certification, so it is not a Report Publication Announcement or a certification filing.
2015-04-24 English
Regulatory Filings 2015
Regulatory Filings
2015-04-07 English
Regulatory Filings 2015
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from a company (Ritter Pharmaceuticals, Inc.) to the SEC staff regarding comments on a Draft Registration Statement on Form S-1. The letter addresses specific SEC comments on the company's registration statement, including requests for clarifications, expansions of disclosures, and revisions to the prospectus and other sections of the registration statement. The document references the Form S-1 registration process, which is related to securities offerings and IPO filings. It is not a financial report, earnings release, or management discussion, but rather a regulatory filing responding to SEC comments on a registration statement. The document is lengthy (15,000 characters) and contains detailed responses to regulatory comments, fitting the profile of a Regulatory Filing (RNS) rather than a report or announcement of a report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2015-03-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.